Heterozygous carriers of a MMR gene alteration are at a greatly increased lifetime risk to develop cancers of the LS tumor spectrum, mainly CRC (25–70%) and endometrial cancer (30–70%) (12). This evidence concerns the gene MRC1 and neoplasm.